METROWEST MEDICAL CENTER
1. Target Overview & Investment Thesis
METROWEST MEDICAL CENTER is a 143-bed suburban community hospital in MIDDLESEX, MA with $208.4M in net patient revenue and a -11.3% operating margin. The hospital serves a payer mix of 34.1% Medicare, 16.3% Medicaid, and 49.6% commercial.
Thesis: Undervalued. Our ML models identify $15.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -11.3% to -3.9% (+736bps).
| Net Revenue HCRIS | $208.4M |
| Current EBITDA COMPUTED | $-23.5M |
| Operating Margin COMPUTED | -11.3% |
| Occupancy HCRIS | 59.3% |
| Revenue / Bed COMPUTED | $1.5M |
| Net-to-Gross HCRIS | 17.2% |
| Distress Probability ML | 47.6% |
2. Market Context & Competitive Position
MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -11.3% places it above the state median. Among 55 size-comparable peers (72-286 beds), the median margin is -10.1%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (72-286), prioritizing same-state peers. 55 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| METROWEST MEDICAL CENTER (Target) | MA | 143 | $208.4M | -11.3% |
| NEWTON WELLESLEY HOSPITAL | MA | 216 | $624.3M | -4.7% |
| CAPE COD HOSPITAL | MA | 239 | $620.3M | -1.3% |
| BERKSHIRE MEDICAL CENTER | MA | 238 | $522.9M | -12.9% |
| NORTH SHORE MEDICAL CENTER | MA | 268 | $503.5M | -12.9% |
| STEWARD ST. ELIZABETHS MEDICAL | MA | 244 | $428.5M | 0.7% |
| BEVERLY HOSPITAL | MA | 261 | $410.6M | -1.6% |
| SAINT VINCENT HOSPITAL | MA | 232 | $404.2M | 0.2% |
| CAMBRIDGE HEALTH ALLIANCE | MA | 225 | $383.9M | -50.0% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $15.3M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $4.4M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $4.2M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $4.1M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $2.5M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $133K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-23.5M |
| + RCM Uplift | +$15.3M |
| Pro Forma EBITDA | $-8.2M |
| Current Margin | -11.3% |
| Pro Forma Margin | -3.9% |
| WC Released (1x) | $8.0M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-36.2M | $-1.7M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-36.2M | $-13.6M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-32.5M | $25.3M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-32.5M | $18.0M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-39.8M | $-66.6M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-39.8M | $-86.2M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 55 hospitals with 72-286 beds
- Same-state prioritization (n=56)
- Comp margins: P25=-18.4% / P50=-10.1% / P75=0.2%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.